<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04889872</url>
  </required_header>
  <id_info>
    <org_study_id>2021-01</org_study_id>
    <nct_id>NCT04889872</nct_id>
  </id_info>
  <brief_title>PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR</brief_title>
  <acronym>PROGRESS</acronym>
  <official_title>The PROGRESS Trial: A Prospective, Randomized, Controlled Trial to Assess the Management of Moderate Aortic Stenosis by Clinical Surveillance or Transcatheter Aortic Valve Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3/&#xD;
      SAPIEN 3 Ultra Transcatheter Heart Valve in subjects with moderate, calcific aortic stenosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, controlled, multicenter study. Subjects will be randomized&#xD;
      to either transcatheter aortic valve replacement (TAVR) with the SAPIEN 3/SAPIEN 3 Ultra THV&#xD;
      or Clinical Surveillance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">June 2037</completion_date>
  <primary_completion_date type="Anticipated">June 2029</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A composite of death, stroke, unplanned cardiovascular hospitalization</measure>
    <time_frame>2 years</time_frame>
    <description>Number of patients that had one of these events</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Aortic Stenosis, Calcific</condition>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>TAVR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter Aortic Valve Replacement (TAVR)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CS</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Clinical Surveillance (CS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SAPIEN 3 / SAPIEN 3 Ultra</intervention_name>
    <description>Patients will be implanted with a SAPIEN 3 / SAPIEN 3 Ultra heart valve</description>
    <arm_group_label>TAVR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. 65 years of age or older at time of randomization&#xD;
&#xD;
          2. Moderate aortic stenosis&#xD;
&#xD;
          3. Subject has symptoms or evidence of cardiac damage/dysfunction&#xD;
&#xD;
          4. The subject or subject's legal representative has been informed of the nature of the&#xD;
             study, agrees to its provisions, and has provided written informed consent.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Native aortic annulus size unsuitable for the THV&#xD;
&#xD;
          2. Anatomical characteristics that would preclude safe placement of the introducer sheath&#xD;
             or safe passage of the delivery system&#xD;
&#xD;
          3. Aortic valve is unicuspid or non-calcified&#xD;
&#xD;
          4. Bicuspid aortic valve with an aneurysmal ascending aorta &gt; 4.5 cm or severe&#xD;
             raphe/leaflet calcification&#xD;
&#xD;
          5. Pre-existing mechanical or bioprosthetic aortic valve&#xD;
&#xD;
          6. Severe aortic regurgitation&#xD;
&#xD;
          7. Prior balloon aortic valvuloplasty to treat severe AS&#xD;
&#xD;
          8. LVEF &lt; 20%&#xD;
&#xD;
          9. Left ventricular outflow tract calcification that would increase the risk of annular&#xD;
             rupture or significant paravalvular leak post-TAVR&#xD;
&#xD;
         10. Cardiac imaging evidence of intracardiac mass, thrombus, or vegetation&#xD;
&#xD;
         11. Coronary or aortic valve anatomy that increases the risk of coronary artery&#xD;
             obstruction post-TAVR&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Généreux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Morristown Medical Center, Morristown, NJ, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeroen J Bax, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center, Leiden, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raj Makkar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center, Los Angeles, CA, USA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edwards THV Clinical Affairs</last_name>
    <phone>949-250-2500</phone>
    <email>THV_CT.gov@Edwards.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atlantic Health System Hospital Corp - Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcatheter aortic valve replacement (TAVR)</keyword>
  <keyword>SAPIEN 3</keyword>
  <keyword>SAPIEN 3 Ultra</keyword>
  <keyword>Moderate aortic stenosis</keyword>
  <keyword>Aortic stenosis</keyword>
  <keyword>Transcatheter heart valve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

